TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07090499: A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.

Sponsor: Pfizer · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 540 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$7,005,768

Rescue Site Savings

+$4,618,152

Unlock Full NCT07090499 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07090499 Rescue Dossier →